10.02.2022 | main topic
Natalizumab treatment during pregnancy in multiple sclerosis—clinical and bioethical aspects of an ongoing debate
verfasst von:
Klaus Berek, Claudia Paganini, Harald Hegen, Gabriel Bsteh, Astrid Grams, Michael Auer, Thomas Berger, Florian Deisenhammer, Franziska Di Pauli, MD, PhD
Erschienen in:
Wiener Medizinische Wochenschrift
|
Ausgabe 15-16/2022
Einloggen, um Zugang zu erhalten
Summary
Background
Natalizumab is an approved treatment for relapsing remitting multiple sclerosis; however, its safety during pregnancy is not formally proven.
Case presentation
We report a woman with multiple sclerosis being treated with natalizumab before pregnancy. After withdrawal of natalizumab, she suffered a severe, disabling rebound. In agreement with the patient, natalizumab was restarted during pregnancy. Our patient improved substantially and gave birth to a healthy boy.
Conclusion
Use of natalizumab during pregnancy may be an option in highly active multiple sclerosis.